Back

Solvonis Therapeutics receives European patent allowance for PTSD drug candidate SVN-114

Verifying
  • Solvonis Therapeutics PLC received a Notice of Allowance for SVN-114’s European patent.
  • The patent covers the chemical compound underlying Solvonis’s lead PTSD drug candidate.
  • The European Patent Office issued the notice for a composition-of-matter patent.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.